These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 8124260

  • 1. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
    Uharek L, Glass B, Gaska T, Zeiss M, Gassmann W, Löffler H, Müller-Ruchholtz W.
    Bone Marrow Transplant; 1993; 12 Suppl 3():S57-60. PubMed ID: 8124260
    [Abstract] [Full Text] [Related]

  • 2. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, Mueller-Ruchholtz W.
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [Abstract] [Full Text] [Related]

  • 3. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L, Glass B, Zeis M, Dreger P, Steinmann J, Löffler H, Schmitz N.
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [Abstract] [Full Text] [Related]

  • 4. Immunotherapeutic aspects of allogeneic peripheral progenitor cells.
    Glass B, Uharek L, Hartung G, Zeis M, Steinmann J, Dreger P, Krönke M, Schmitz N.
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S3-8. PubMed ID: 9712483
    [Abstract] [Full Text] [Related]

  • 5. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M, Uharek L, Glass B, Vosskötter W, Dreger P, Schmitz N, Steinmann J.
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [Abstract] [Full Text] [Related]

  • 6. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ.
    J Clin Invest; 1998 May 01; 101(9):1835-42. PubMed ID: 9576746
    [Abstract] [Full Text] [Related]

  • 7. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep 01; 5(3):145-52. PubMed ID: 10641572
    [Abstract] [Full Text] [Related]

  • 8. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 9. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P, Vourka-Karussis U, Weiss L, Slavin S.
    J Immunol; 1993 Nov 01; 151(9):4803-10. PubMed ID: 8409438
    [Abstract] [Full Text] [Related]

  • 10. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L.
    Bone Marrow Transplant; 1990 Sep 01; 6(3):155-61. PubMed ID: 2252954
    [Abstract] [Full Text] [Related]

  • 11. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells.
    Glass B, Uharek L, Zeis M, Loeffler H, Mueller-Ruchholtz W, Gassmann W.
    Br J Haematol; 1996 May 01; 93(2):412-20. PubMed ID: 8639441
    [Abstract] [Full Text] [Related]

  • 12. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z.
    Eur J Haematol; 2008 Sep 01; 81(3):226-35. PubMed ID: 18573173
    [Abstract] [Full Text] [Related]

  • 13. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ, Thompson JS, Jennings CD, Brown SA.
    Transplantation; 1995 Oct 27; 60(8):821-7. PubMed ID: 7482742
    [Abstract] [Full Text] [Related]

  • 14. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
    Chen GH, Wu DP, Sun AN, Yang MZ, Wang Y, Tang XW, Chang HR, Feng YF, Zhu ZL.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug 27; 29(8):526-30. PubMed ID: 19112915
    [Abstract] [Full Text] [Related]

  • 15. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW, Shamim F, Hamon M, Macdonald ID, Prentice HG.
    Exp Hematol; 1995 Dec 27; 23(14):1530-4. PubMed ID: 8542943
    [Abstract] [Full Text] [Related]

  • 16. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD, Becker EE, Truitt RL.
    Biol Blood Marrow Transplant; 1999 Dec 27; 5(3):123-32. PubMed ID: 10392958
    [Abstract] [Full Text] [Related]

  • 17. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y, Guo K, Chen Y, Song Z, Li J, Deng L.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug 27; 23(8):411-4. PubMed ID: 12411044
    [Abstract] [Full Text] [Related]

  • 18. Graft-versus-leukemia effect in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias.
    Aizawa S, Sado T, Kamisaku H, Nemoto K, Yoshida K.
    Bone Marrow Transplant; 1994 Feb 27; 13(2):109-14. PubMed ID: 8205078
    [Abstract] [Full Text] [Related]

  • 19. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.
    Weiss L, Reich S, Slavin S.
    Bone Marrow Transplant; 1995 Sep 27; 16(3):457-61. PubMed ID: 8535320
    [Abstract] [Full Text] [Related]

  • 20. The effects of polyinosinic:polycytidylic acid (pI:C) on the graft-vs-host (GVH) reaction. II. Increased NK-mediated rejection on C57BL/6 lymphocytes by (C57BL/6 X A)F1 mice.
    Peres A, Nestel FP, Seemayer TA, Lapp WS.
    J Immunol; 1986 Dec 01; 137(11):3420-7. PubMed ID: 3537120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.